Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusidic acid repurposing for onchocerciasis
ISRCTN73567594Phase 2Recruiting
- Sponsor
- University of Buea
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fusidic acid, albendazole and doxycycline in onchocerciasis (8 arms), sponsored by University of Buea. Started Aug 2026; status: recruiting.
02
Drugs
fusidic acidalbendazoledoxycycline
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on ISRCTN73567594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73567594.